Nasdaq Ymab News Today

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report)’s stock price rose 5.9% during mid-day trading on Monday . The company traded as high as $17.49 and last traded at $17.22. Approximately 119,509 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 406,738 shares. The stock had previously closed […]

Wedbush reiterated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research report released on Monday morning, RTT News reports. They currently have a $18.00 price objective on the stock, up from their prior price objective of $12.00. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q4 2024 earnings at ($0.19) […]

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) were up 2.8% on Tuesday . The company traded as high as $12.50 and last traded at $12.45. Approximately 32,320 shares changed hands during trading, a decline of 92% from the average daily volume of 411,775 shares. The stock had previously closed at $12.11. Analysts […]

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been given a consensus recommendation of “Hold” by the seven analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The […]

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given an average recommendation of “Hold” by the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy […]

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) Director Johan Wedell-Wedellsborg purchased 62,516 shares of the stock in a transaction that occurred on Monday, November 27th. The shares were purchased at an average price of $5.49 per share, with a total value of $343,212.84. Following the completion of the acquisition, the director now directly owns […]

HC Wainwright reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note released on Wednesday, Benzinga reports. The brokerage currently has a $11.00 price target on the stock. HC Wainwright also issued estimates for Y-mAbs Therapeutics’ FY2023 earnings at ($0.65) EPS, Q1 2024 earnings at ($0.19) EPS, Q2 […]

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have earned an average rating of “Hold” from the ten analysts that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the […]

Avestar Capital LLC acquired a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $68,000. A number of other hedge funds have […]

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been assigned a consensus rating of “Hold” from the eleven research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and four have assigned a buy recommendation to the […]